Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies
Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.
Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.
The company is developing three novel first-in-class drug products across multiple critical care indications. Its lead product, Centhaquine, is for Hypovolemic Shock where a new therapeutic is greatly needed. Pharmazz’s second compound, Sovateltide, is for cerebral ischemic stroke, Alzheimer’s disease, and other neurodegenerative diseases. A third compound is being developed for treatment of diabetic ketoacidosis and to eliminate opioid tolerance.
Incorporated - October
Licensing agreement with Midwestern The University - January
Pharmazz India Private Limited started - March
Licensing agreement with University of Illinois - January
Centhaquine Phase I - September
Sovateltide Phase I - July
Centhaquine Phase II - December
Sovateltide Phase II for Stroke - August
Sovateltide Phase II for Alzheimer’s disease - August
Sovateltide Phase II for Acute Spinal Cord Injury - October
Centhaquine Phase III - December
Sovateltide Phase III for Stroke - July
Centhaquine Market Approval (India) - May
Lyfaquin® (centhaquine) launched - November